Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03646097
Other study ID # OPTICO-Integration II
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 21, 2018
Est. completion date March 15, 2019

Study information

Verified date April 2019
Source Charite University, Berlin, Germany
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Intracoronary optical coherence tomography (OCT) imaging allows for high-resolution characterization of coronary lesions. Difficulties in matching cross-sectional OCT-images with angiographic lesion localization, however, may limit its clinical utilization. The investigators sought to prospectively assess the impact of a novel system of real-time OCT-coregistration with angiography (ACR) compared to OCT alone and to the clinical standard proceeding (angiographic guided-PCI) all used for coronary lesion evaluation before percutaneous coronary interventions (PCI). The investigators hypothesize that the use of ACR will lead to less incidence of insufficient covered coronary lesions (geographical mismatch) and/or a less rate of edge dissections after PCI (combined primary study endpoint)


Description:

In this randomized blinded pilot-study the effect of pre-PCI planning by angiographic-co-registered OCT (ACR) compared to OCT or angiographic evaluation alone with respect to the entire result after PCI will be investigated. A special focus (primary endpoint) will be on the incidence of geographical mismatch (GM) and/or major edge dissections. Eligible patients will be randomized in three groups.

Group 1 Pre-PCI-OCT: Patients underwent OCT-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on OCT findings.

Group 2: Pre-PCI-ACR: Patients underwent ACR-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on ACR-findings.

Group 3:OCT-Blinded/Angiographic guided PCI: Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators only based on angiographic lesion evaluation (standard care).

For outcome analysis all study groups underwent post-PCI-OCT imaging as soon as investigators assume angiographic justiciable PCI-results (TIMI III, no residual stenosis > 50%; no angiographic definable or suspicious edge dissections, angiographic acceptable stent expansion without evidence for malapposition). OCT imaging analysis will be performed within a OCT core-lab by two investigators blinded for the randomization group.


Recruitment information / eligibility

Status Completed
Enrollment 84
Est. completion date March 15, 2019
Est. primary completion date November 29, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Patient with indication for coronary angiography for angina (stable or unstable), silent ischemia (a visually estimated target lesion diameter stenosis of =70%, a positive invasive or non-invasive test must be present), or NSTE-ACS

- male or non pregnant female patient

- Signed written informed consent

Exclusion Criteria:

- Known neoplasia on treatment / without a curative therapeutic approach

- Presence of one or more co-morbidities which reduces life expectancy to less than 24 months

- Estimated creatinine clearance <40 ml/min

- Cardiogenic shock

- Hemodynamic instability because of arrhythmia

- Known left ventricular ejection fraction (LVEF) <30%.

- Therapy requiring psychiatric disorder

- Patient is participating in any other investigational drug or device clinical trial that has not reached its primary endpoint.

- Women who are pregnant or breastfeeding

- Refusal of study participation

Study Design


Intervention

Procedure:
Angio-PCI
PCI only with angiography and without OCT findings
OCT-PCI
PCI with OCT-measurements but no transfer of landingzone-markers to angiography
ACR-PCI
PCI with OCT-measurements and transfer of landingzone-markers to angiography

Locations

Country Name City State
Germany Charité - Universitätsmedizin Berlin Berlin

Sponsors (1)

Lead Sponsor Collaborator
Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of a combined endpoint based on "major edge dissections" (I) AND/OR "geographical mismatch" (II) [%] Analysis of primary endpoint will be assessed by evaluation of proximal and/or distal stent end.
I) Major edge dissection (MED):
Major: =60 degrees of the circumference of the vessel at site of dissection and/or =3 mm in length
II) Geographical mismatch (GM):
Untreated plaque with a minimal lumen area <4,5mm2 within 5mm of the reference segment.
In the postPCI-OCT analysis it is considered as no geographical mismatch, if:
the segment of the lesion is fully covered AND
the stent protrudes maximal 5mm beyond the predetermined landing zone.
If one of these criteria is not fulfilled, it is considered as geographical mismatch
Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Incidence of "major edge dissections" [%] All secondary endpoints of OCT will be assessed by evaluation of proximal and/or distal stent end/segment. Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Incidence of "all edge dissections" (major (I) and minor (II)) [%] (I) =60 degrees of the circumference of the vessel at site of dissection and/or =3 mm in length (II) Any visible edge dissection <60 degrees of the circumference of the vessel and < 3 mm in length Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Incidence of "geographical mismatch" [%] see primary endpoint Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Stent expansion [%] Defined by the MSA achieved relative to the proximal or distal reference segments.
The stent length is divided into 2 equal segments (proximal and distal), and the MSA is determined in each segment.
Optimal stent expansion: The MSA of the segment is =95% of the related reference lumen area
Acceptable stent expansion: The MSA of the segment is =90% and <95% of the related reference lumen area
Unacceptable stent expansion: The MSA of the segment is <90% of the related lumen area
Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Inacceptable stent expansion [%] see outcome 5 Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Incidence of "malapposition" [%] Incompletely apposed stent struts in at least 5 consecutive OCT-frames (defined as stent struts clearly separated from the vessel wall (lumen border/plaque border) without any tissue behind the struts with a distance from the adjacent intima of =0.2 mm and not associated with any side branch).
Malapposition will be further classified as:
A) Major: If associated with stent underexpansion (unacceptable stent expansion as defined above) B) Minor: If not associated with significant underexpansion (optimal or acceptable stent expansion as defined above) C) Major and minor
Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Distance between target and actual lesion coverage [mm] Defined as the distance between target landing zone and actual landing zone of stent location (proximal and distal end). Therefore, the lesion is divided in two equal halves, so that every segment (proximal and distal) can be analyzed for itself. Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Minimal Stent Area (MSA) of target lesion [%] Minimal lumen area covered by stent. Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Acute Luminal Gain of target lesion [mm] Gain of Minimal Lumen Diameter (MLD) between prePCI- and postPCI-OCT Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Procedure time [min] Time from reaching the ostium with the guide catheter until pullback of the last one. Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Total fluoroscopy time [min] Total time required for diagnostic angiography and PCI. Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Total contrast volume [ml] Total amount of contrast used for entire intervention (including OCT-pullbacks) Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Total stent length [mm] Addition of each stent length which were used for target lesion Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Total number of stents Number of stents which were used for target lesion Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Maximal stent diameter [mm] Maximal stent diameter used for target lesion Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Complications associated with OCT-examination [%] Complications between advancing and pullback of OCT catheter Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary Complications during hospitalization [%] Defined as: new ACS; stent thrombosis of study culprit lesion; new unplaned coronary angiography; new revascularization (PCI/CABG); apoplex/TIA; pacemaker implantation; anaphylactic shock; contrast-induced nephropathy; bleeding; death Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary DOCE within target lesion [%] Device-oriented composite endpoint within the target lesion. Defined as cardiovascular death, myocardial infarction OR target-lesion revascularization. This composite endpoint will be checked during a follow up after 1 and 3 months. Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours
See also
  Status Clinical Trial Phase
Completed NCT04097912 - Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
Completed NCT01941355 - Trial of Rehabilitation in Phase 1 After Coronary Artery Bypass Grafting N/A
Active, not recruiting NCT03603210 - Outcomes of Drug Coated Balloon Angioplasty, A UK Real Life Experience From 2009 to 2015
Completed NCT00151658 - Sirolimus Eluting Stents in Complex Coronary Lesions (SCANDSTENT) N/A
Recruiting NCT04193475 - Machine Learning in Quantitative Stress Echocardiography
Completed NCT02290262 - SheppHeartCABG - Phase One Rehabilitation After Coronary Artery Bypass Grafting N/A
Active, not recruiting NCT03736018 - Randomised Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients N/A
Completed NCT02849067 - Hemodynamic Responses of Stable Ischemic Heart Disease Patients to a Comedy Session N/A
Recruiting NCT05045118 - The Impact of Structured Patient Education Material (SPEM) in Improving Clinical and Behavioural Outcomes in Home-based Cardiac Rehabilitation Program Participants: A Pilot Study N/A
Completed NCT04901767 - Coronary Artery Endothelial Dysfunction With Drug Coated Balloons
Enrolling by invitation NCT03674255 - Echocardiography: Value and Accuracy at REst and STress
Active, not recruiting NCT03171311 - The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER) N/A
Recruiting NCT04768283 - Cardiac Rehabilitation and Additional Physical Training in Elderly Patients After Acute Coronary Syndrome N/A
Completed NCT02315001 - Liraglutide to Improve corONary Haemodynamics During Exercise streSS Phase 2
Completed NCT01796353 - Effects of a Comprehensive Sexual Rehabilitation Programme in Heart Patients N/A
Recruiting NCT04061525 - Motion and IntraCoronary Ecg Ischemia Development Study (MICE)
Recruiting NCT04674449 - iCorMicA - Stratified Medicine in Angina N/A
Active, not recruiting NCT02623140 - BIOFREEDOM Stent Versus ORSIRO Stent: SORT OUT IX Phase 4
Completed NCT02053818 - Remifentanil/Sufentanil for CABG+/-AVR Evaluated by Recovery, Cognitive Function, Haemodynamics and Biochemical Markers. Phase 4
Recruiting NCT04014140 - iFR Guided Coronary Artery Bypass Grafting Surgery